The Polish Diabetes Registry for Adults — a pilot study by Witek, Przemysław W. et al.
PRACA ORYGINALNA ISSN 2084–4441
www.dk.viamedica.pl 3
Address for correspondence: Dr Przemyslaw Witek, M.D., Ph.D.
Department of Metabolic Diseases, University Hospital of Krakow
ul. Kopernika 15, 31–501 Kraków, Poland
tel. +48 12 424 83 05
fax. +48 12 421 97 86
e-mail: przemyslawwitek@yahoo.co.uk
Diabetologia Kliniczna 2012, tom 1, 1, 3–11
Copyright © 2012 Via Medica
Nadesłano: 21.02.2012 Przyjęto do druku: 06.03.2012
Przemysław W. Witek1, Paweł Wołkow3, Julita Stancel-Możwiłło1,
Katarzyna Wojtyczek1, Jacek Sieradzki1, 2, Maciej Małecki1, 2
1Department of metabolic diseases, University Hospital of Krakow, Poland
2Department and chair of metabolic diseases, Jagellonian University of Krakow, Poland
3Department of pharmacology, Jagellonian University of Krakow, Poland
The Polish Diabetes Registry for Adults
— a pilot study
Narodowy Rejestr Chorych na Cukrzycę w Polsce — program pilotażowy
ABSTRACT
Background. Over the years 2006–2009 a pilot project
of the Polish Diabetes Registry for Adults financed
by the Polish Ministry of Health was performed. The
objective was to assess outpatient diabetes care
a few years after joining the European Union.
Material and methods. Questionnaires for randomly
enrolled patients were completed by diabetologists in
39 outpatient diabetes centers in different parts of
Poland. Data concerning age, sex, BMI, diabetes type
and duration, hypoglycemic treatment, glycated
haemoglobin (HbA1c), lipids levels, blood pressure (BP),
diabetes complications, concomitant diseases and their
treatment, and other aspects of medical care were
collected. The questionnaires were analysed centrally.
Results. Data on 7606 individuals were available:
15.0% with type 1 diabetes (T1DM); 80.9% with type
2 diabetes (T2DM); 1.9% with other types of diabetes;
and 2.2% with gestational diabetes. T1DM and T2DM
cohorts consisted of 1134 (52.4% women) and 6119
(55.5% women) patients, mean age 40.9 and 63.8
years, mean diabetes duration 14.6 and 9.7 years,
respectively. Mean HbA1c for T1DM and T2DM was
7.69 and 7.25%. Lipid parameters for T1DM and
T2DM were as followed: mean total cholesterol (TC)
4.84 and 5.06 mmol/l; mean LDL-cholesterol (LDL)
2.73 and 2.90 mmol/l; mean HDL-cholesterol (HDL)
1.58 and 1.30 mmol/l; mean triglycerides (TG) 1.26
and 1.95 mmol/l; mean blood pressure (BP) 127.4/
/77.7 and 139.8/81.8 mmHg. The following proportion
of the patients within target were recorded: for
HbA1c (£ 7.0% and £ 6.5%): T1DM 39.4 and 22.6%,
T2DM 52.1 and 32.8%; for TC levels (< 4.5 mmol/l):
T1DM 40.1%, T2DM 32.6%; for TG levels (< 1.7 mmol/l):
T1DM 82.1%, T2DM 53.2%; for BP (< 130/80 mm Hg):
T1DM 31.9%, T2DM 12.9%, respectively. Prevalence
of microvascular complications among T1DM and
T2DM was as followed: retinopathy 38,4 and 23,4%;
nephropathy 15,2 and 8,5%; peripheral neuropathy
25.3 and 25.4%; autonomic neuropathy 9,6 and 5,4%.
Conclusions. The data show the current quality of
diabetes care in Poland, which seems to show some
improvement as compared to the DEPAC survey
performed at the accession to EU (2004). Nevertheless,
the current Registry also indicates that most patients
still do not meet the criteria of diabetes control
defined by the local and international guidelines.
(Diabet. Klin. 2012; 1, 1: 3–11)
Key words: diabetes registry, treatment of diabetes,
chronic complications of diabetes
STRESZCZENIE
Wstęp. Pilotażowy projekt Rejestru Dorosłych Cho-
rych na Cukrzycę w Polsce został przeprowadzony
w latach 2006–2009. Został on sfinansowany z fun-
duszy Ministerstwa Zdrowia. Celem projektu była
Diabetologia Kliniczna 2012, tom 1, nr 1
4 www.dk.viamedica.pl
ocena jakości opieki diabetologicznej w kilka lat po
przystąpieniu Polski do Unii Europejskiej.
Materiał i metody. Kwestionariusze dotyczące danych
pacjentów z cukrzycą były wypełniane przez lekarzy
diabetologów w 39 różnych ośrodkach diabetolo-
gicznych w Polsce. Dane zawarte w kwestionariu-
szach zawierały pytania o: wiek, płeć, BMI, typ i czas
trwania cukrzycy, rodzaj leczenia hipoglikemizujące-
go, HbA1c, profile glikemii, lipidogram, ciśnienie tęt-
nicze, powikłania cukrzycy, choroby towarzyszące
i ich leczenie oraz inne aspekty opieki. Kwestiona-
riusze były analizowane w centralnym ośrodku.
Wyniki. Uzyskano dane 7606 pacjentów: 15,0%
z typem 1 cukrzycy (T1DM), 80,9% z typem 2 cukrzycy
(T2DM), 1,9% z innymi typami cukrzycy i 2,2% z cu-
krzycą ciążową. Grupa chorych z T1DM i T2DM cha-
rakteryzowała się odpowiednio: liczebnością 1134
(52,4% kobiet) i 6119 (55,5% kobiet), średnim wie-
kiem 40,9 i 63,8 lat, średnim czasem trwania cukrzy-
cy 14,6 i 9,7 lat. Średni poziom HbA1c wynosił dla
T1DM i T2DM odpowiednio 7,69 i 7,25%. Parametry
gospodarki lipidowej dla T1DM i T2DM wynosiły:
cholesterol całkowity 4,84 i 5,06 mmol/l; LDL-chole-
sterol 2,73 i 2,90 mmol/l; HDL-cholesterol 1,58 i 1,30
mmol/l; triglicerydy 1,26 i 1,95 mmol/l; ciśnienie tęt-
nicze 127,4/77,7 i 139,8/81,8 mmHg. Odsetek pacjen-
tów spełniających kryteria wyrównania wynosił od-
powiednio dla: HbA1c £ 7,0% i £ 6,5%: T1DM 39,4
i 22,6%, T2DM 52,1 i 32,8%; cholesterol całkowity
< 4,5 mmol/l: T1DM 40,1%, T2DM 32,6%; triglicery-
dy < 1,7 mmol/l: T1D 82,1%, T2D 53,2%; ciśnienie
tętnicze < 130/80 mm Hg: T1DM 31,9%, T2DM
12,9%. Częstość występowania mikronaczyniowych
powikłań cukrzycy wynosił odpowiednio dla chorych
z T1DM i T2DM: retinopatia 38,4 i 23,4%; nefropatia
15,2 i 8,5%; neuropatia obwodowa 25.3 i 25.4%;
neuropatia autonomiczna 9,6 i 5,4%.
Wnioski. Dane uzyskane w Rejestrze obrazują obec-
ny stan opieki diabetologicznej w Polsce, który wy-
kazuje tendencję do poprawy w porównaniu do ba-
dania DEPAC przeprowadzonego w krajach Europy
środkowo-wschodniej, w tym w Polsce w okresie
przystąpienia do Unii Europejskiej (2004). Pomimo
tego trendu większość pacjentów wciąż nie spełnia
kryteriów wyrównania cukrzycy rekomendowanych
przez krajowe i międzynarodowe zalecenia. (Diabet.
Klin. 2012; 1, 1: 3–11)
Słowa kluczowe: rejestr chorych na cukrzycę,
leczenie cukrzycy, przewlekłe powikłania cukrzycy
Introduction
Diabetes mellitus becomes an epidemic of XXI
century, mainly as a result of food excess and se-
dentary lifestyle [1]. Chronic microvascular (retino-
pathy, nephropathy and neuropathy with diabetic
foot syndrome) and macrovascular (coronary heart
disease, brain and peripheral arteries disease) com-
plications are major cause of disability and prema-
ture mortality in diabetic patients [2]. Diabetes ge-
nerates not only medical and social but also econo-
mic problems, becoming a hard burden for health
care budgets [3]. The large clinical trials, DCCT in
type 1 (T1DM) [4] and UKPDS in type 2 diabetes
mellitus (T2DM) [5] proved that long term glycemic
control reduces frequency of chronic microvascular
complications. Prolonged observation of T1DM pa-
tients in DCCT/EDIC study showed reduced frequen-
cy of macroangiopathy in previously intensively tre-
ated patients [6].
The targets for treatment have not been une-
quivocally determined for specific groups of patients.
For example lack of improvement in cardiovascular
outcomes, especially in elderly patients and even
increased mortality was observed in ACCORD and
VADT trials in intensively treated group [7, 8]. Possi-
bly slower, more prolonged restoration of glucose
control would have more beneficial effect [9].
Since 2005, The Polish Diabetes Association
(PDA) releases the annual clinical recommendations
for diabetes care in Poland. Every year they are mo-
dified according to newest evidence-based know-
ledge. In the years 2006-8 the HbA1c targets recom-
mended by PDA was £ 6.1% and £ 6.5, lower in
patients with low risk of hypoglycaemia. In 2009
the HbA1c targets were changed. Recommended
value for T1DM patients and for T2DM patients with
short duration of diabetes was £ 6.5% and for the
rest of T2DM patients £ 7.0%.
Appropriate glycemic control is not sufficient
to prevent chronic complications of diabetes. The
full metabolic control includes treatment of hyper-
glycemia, lipid abnormalities, hypertension and nor-
malization of body weight. The advantage of the
multifactorial intervention has been proven in T2DM
patients with microalbuminuria [10]. The effective-
ness of the treatment of lipid abnormalities has well-
documented beneficial impact on survival and deve-
lopment of chronic complications, first of all macro-
angiopathy [11]. It still remains controversial how low
should be target blood pressure in diabetic patients.
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In the years 2007–2009 the target blood pressure
recommended by PDA was below 130/80 mmHg.
Valuable data about the quality of treatment
in various geographical regions and countries come
from Diabetic Registries (DR). DR could have local
or global range. Data collected in DR are provided
by primary as well as secondary medical care. Based
on the stored information, it is possible to estimate
the quality of diabetes care and current costs of he-
alth care system that should be provided for diabetic
patients. Moreover, monitoring these parameters in
time allows to predict epidemiological trends of pre-
valence of diabetes and its complications. It gives
a prognosis of future expenditures in diabetes care.
In year 2004 when Central and Eastern Euro-
pean countries accessed the European Union (EU)
large survey DEPAC that analysed the level of diabe-
tes care in these region was performed [12]. In year
2006 the Polish Health Ministry sponsored a grant
for the Polish Diabetes Registry for Adults. Data col-
lected in this registry comes from 2007–2009, thus
comparison of these two surveys can give same in-
formation on the change in the quality of diabetes
care in Poland a few years after accession to EU.
Materials and methods
The pilot Polish Diabetes Registry for Adults
was based on a questionnaire that concerned many
aspects of diabetes care. The questionnaires were
one page double sided papers that were sent to se-
cond-degree diabetological centres selected earlier
by regional consultants. All biochemical measures
were performed in local laboratories. The question-
naires were filled based on current records of pa-
tient’s medical history and sent back to the coordi-
nating centre that was located in Department of
Metabolic Diseases in Krakow. The data from qu-
estionnaires were verified by medical specialists and
stored in database by internet-based application.
The questionnaires included questions on the follo-
wing data:
— basic demographic data;
— type of diabetes and criterion used for diagnosis
(if available);
— year of diagnosis and beginning of treatment
(oral drugs, insulin);
— concomitant diseases;
— vital signs and anthropometric measurements;
— results of laboratory tests preceeding the visit
(HbA1c, glucose profile, lipids, C-peptide, immu-
ne markers of type 1 diabetes), frequency of hy-
poglycaemia;
— number of hospitalisations in the year preceeding
the visit;
— current diabetes treatment, number of anti-dia-
betic drugs and test-strips prescribed at visit;
— current treatment of concomitant diseases, num-
ber of other drugs prescribed at visit;
— history and current status of chronic complica-
tions of diabetes;
— referral to lab tests and consultations of other
specialists.
In this article only partial data collected in the
questionnaires were analysed.
The Polish Diabetes Registry for Adults inclu-
ded only patients treated in second-degree level of
medical care. In late 2006 we obtained the list of 40
diabetic centres selected by regional consultants to
whom in 2007 we sent 100 questionnaires per cen-
tre. We attached a detailed manual how to comple-
te questionnaire. In each centre, all consecutive 100
patients attending from the starting point were in-
cluded. Finally we obtained 3334 filled questionna-
ires and positively verified 3327 of them.
In 2008 4 more centres were included and 108
questionnaires were sent to each participant cen-
tre. We instructed the physicians to select patients
that have not been recorded previously. Because of
administrative obstacles we prolonged duration of
registering to March 2009. In January 2009 we sent
800 more questionnaires to selected centres and
collected them before deadline March 31-th. Even-
tually in 2008-9 we obtained more 4313 filled qu-
estionnaires and positively verified 4279 of them.
Results
Overall we obtained the total number of 7647
filled questionnaires from 39 centres. 41 patients
had two visits completed. Only data from the first
visit were chosen for the analysis. Thus, we verified
and analysed data of 7606 patients. Out of these
subjects, 1134 (14.91%) had T1DM, 6119 (80.45%)
had T2DM, 147 (1.93%) one of other specific types
of DM, 165 (2.17%) gestational DM and in 41
(0.54%) type of DM was unspecified. Of these 4225
(55.55%) were women. The results of patients with
other types of diabetes, gestational diabetes and
unspecified diabetes are not discussed because of
the small number of subjects.
Table 1 shows clinical characteristic of patients
(age, gender, duration of diabetes, anthropometric
measures) and data on glycaemic, lipid and blood
pressure control. Mean HbA1c for T1DM and T2DM
was 7.69% and 7.25%, respectively. Only 39.4% and
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22.6% of T1DM patients fulfilled the criteria of HbA1c
£ 7.0% and HbA1c £ 6.5%, respectively. In T2DM
patients these numbers were 52.1% and 32.8%, re-
spectively. T1DM patients had better lipid parame-
ters and blood pressure control than T2DM subjects.
Out of T2DM patients, 2.4% were without any
pharmacological treatment, 42.2% were on oral anti-
diabetic drugs, 20.9% on insulin only and 34.6%
were on combined therapy with insulin and oral
drugs.
Table 2 shows the percentage of different oral
anti-diabetic drugs and their combinations used in
T2DM. Only metformin, sulfonylurea derivatives and
alpha-glucosidase inhibitors are shown. Other drugs
like glinides, glitazones and incretin axis medications
were not included because of a very small number
of patients using them. The most popular model was
the combination of metformin with sulfonylurea. It
was used in 20.3% T2DM subjects and in 48.2% of
T2DM subjects treated with oral drugs only.
Different combination of oral anti-diabetic
drugs with insulin in T2DM patients were shown in
Table 3. The most frequent model was a combina-
tion of insulin with metformin.
The percentage of total number of patients
with T2DM treated with particular types of oral an-
Table 1. Clinical characteristic of the examined diabetic patients
Unit Data type 1 Type 1 Data type 2 Type 2 Data type 1 & 2 Type 1 & 2
Age Years 1134 40.9 ±14.5 6119 63.8 ± 10.4 7253
Gender (males) (%) 1134 47.66119 44.6 7253
Duration of diabetes Years 14.6 ± 11.2 9.7 ± 7.6
BMI total [kg/m2] 1072 25.00 ± 3.92 5838 31.28 ± 5.27 6910 30.31 ± 5.57
BMI males [kg/m2] 511 25.50 ± 3.67 2599 30.48 ± 4.79 3110 29.66 ± 4.98
BMI females [kg/m2] 561 24.54 ± 4.09 3239 31.92 ± 5.55 3800 30.83 ± 5.96
Waist total [cm] 813 84.9 ± 12.6 4866 101.7 ± 13.2 5679 99.3 ± 14.3
Waist males [cm] 383 90.7 ± 11.2 2118 104.4 ± 12.5 2501 102.3 ± 13.3
Waist females [cm] 430 79.8 ± 11.6 2748 99.7 ± 13.3 3178 97.0 ± 14.7
WHR total 695 0.87 ± 0.10 4116 0.93 ± 0.09 4811 0.92 ± 0.09
WHR males 327 0.93 ± 0.08 1809 0.97 ± 0.08 2136 0.97 ± 0.08
WHR females 368 0.81 ± 0.08 2307 0.89 ± 0.08 2675 0.88 ± 0.09
HbA1c 868 7.69 ± 1.64 4043 7.25 ± 1.42 4911 7.33 ± 1.47
£ 7.0% (%) 39.4 52.1 49.9
£ 6.5% (%) 22.6 32.8 31.0
Fasting glycemia [mg/dl] 134.0 124.6 126.1
Pre-prandial glycaemia [mg/dl] 133.3 125.4 126.6
Postprandial glycaemia [mg/dl] 146.6 147.7 147.6
Mean glycaemia [mg/dl] 140.0 138.8 138.9
Total cholesterol [mmol/l] 559 4.84 ± 0.99 3198 5.06 ± 1.16 3757 5.03 ± 1.14
< 4.5 mM (%) 40.07% 32.61% 33.72%
HDL-cholesterol [mmol/l] 442 1.58 ± 0.48 2467 1.30 ± 0.51 2909 1.35 ± 0.51
> 1.0 (1.3) mM (%) 83.26% 60.52% 63.97%
LDL-cholesterol [mmol/l] 410 2.73 ± 0.82 2263 2.90 ± 0.99 2673 2.87 ± 0.96
< 2.6 mM (%) 44.88% 40.65% 41.30%
Triglycerides [mmol/l] 503 1.26 ± 0.87 2922 1.95 ± 1.61 3425 1.85 ± 1.55
< 1,7 mM (%) 82.11% 53.15% 57.40%
Systolic BP [mm Hg] 1090 127.4 ± 16.1 5978 139.8 ± 18.7 7068 137.9 ± 18.9
< 130 mm Hg (%) 54.50% 24.09% 28.78%
Diastolic BP [mm Hg] 1090 77.7 ± 9.1 5977 81.7 ± 10.4 7067 81.1 ± 10.3
< 80 mm Hg (%) 42.11% 27.67% 29.90%
Blood pressure (%) 1090 31.93%5977 12.89% 706715.82%
< 130/80 mm Hg
Heart rate [min–1] 1033 77.0 ± 8.2 5735 76.2 ± 8.9 6768 76.3 ± 8.8
*For males > 1.0 mmol/l; for females > 1.3 mmol/l
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tidiabetic drugs are presented in Table 4. The most
common oral drug was metformin. There were
62,38% T2DM patients treated with metformin.
The use of different types of insulin in both
types of diabetes is shown in Table 5. The most po-
pular insulin types used in T1DM were rapid analo-
gues and NPH insulin while in T2DM human insulin
mixtures were the most frequently used.
Table 6 shows the prevalence of chronic com-
plication of diabetes within analysed population.
Occurrence of chronic microvascular complications
of diabetes (retinopathy, nephropathy and autono-
mic neuropathy) was higher in T1DM than T2DM
patients. Peripheral neuropathy had similar occur-
rence in both types of diabetes. Macrovascular com-
plications were much more frequent in T2DM than
T1DM patients.
Discussion
The Polish Diabetes Registry for Adults as
shown above is one of the first attempts to descri-
be most aspects of diabetes care in Poland. The
data obtained from second-degree diabetological
centres are comparable with data collected in DE-
PAC trial that was an international survey conduc-
ted in central and eastern European countries at
accession to EU. The outcomes of this earlier trial
did not find a significant difference between qua-
Table 2. Percentage of different combination of oral anti-
diabetic drugs in T2DM
Oral drugs combination Percentage of patients
with T2DM
Without treatment at all 0.3%
Only diet 0.3%
Diet and exercise 1.8%
Total without pharmacotherapy 2.4%
Monotherapy with sulfonylurea 6.9%
Monotherapy with metformin 10.7%
Monotherapy with alpha- 0.6%
-glucosidase inhibitors
Sulfonylurea + metformin 20.3%
Sulfonylurea + alpha-glucosidase 1.4%
inhibitors
Metformin + alpha-glucosidase 0.6%
inhibitors
Sulfonylurea + metformin + 1.7%
+ alpha-glucosidase inhibitors
Other combinations 0.2%
Total treated with oral drugs 42.2%
Table 3. Combination therapy: oral anti-diabetic drugs
and insulin in T2DM
T2DM T2DM
total on insulin
Monotherapy with insulin 20.9% 37.6%
Insulin + sulfonylurea 3.0% 5.3%
Insulin + metformin 20.3% 36.6%
Insulin + alpha-glucosidase inhibitors 1.9% 3.4%
Insulin + sulfonylurea + metformin 6.9% 12.4%
Insulin + sulfonylurea + alpha- 0.7% 1.2%
-glucosidase inhibitors
Insulin + metformin + alpha- 1.4% 2.5%
-glucosidase inhibitors
Insulin + sulfonylurea + metformin + 0.5% 0.9%
+ alpha-glucosidase inhibitors
Insulin + any oral hypoglycaemic drugs 34.6% 62.4%
Table 4. Percentage of T2DM patients treated with par-
ticular non-insulin drugs with or without combination
with insulin
Therapy Percentage of patients
Metformin 62.4%
Sulfonylurea derivative 41.3%
Alpha-glucosidase inhibitors 8.6%
Tiazolidynodiones 0.02%
Glinides 0.00%
GLP-1 receptor agonists 0.03%
DPP-IV inhibitors 0.16%
Table 5. Percentage of patients treated with particular
types of insulin
Type 1 Type 2
DM  DM
Human short-acting insulin 21.4% 10.0%
Rapid-acting analogue 69.3% 9.0%
Insulin NPH 53.6% 16.7%
Long-acting analogue 24.6% 2.0%
Mixture of human insulin 10.1% 21.6%
Mixture of analogue insulin 8.8% 16.3%
Bovine or porcine insulin 0.0% 0.0%
Continuous subcutaneous insulin infusion 4.7% 0.0%
No data 1.1% 0.0%
Total insulin 100% 55.4%
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lity of diabetes care between central-eastern and
western Europe [12].
The Polish Diabetes Registry for Adults collec-
ted data several years after the accession to EU. The
comparison with previous data obtained in the DE-
PAC trial gives some answers concerning the chan-
ges in diabetes care after the geopolitical transfor-
mation in this part of Europe.
A mean HbA1c level in Registry was 7.33%, the
values were 7.69% and 7.25% in T1DM and T2DM
subjects, respectively. Values of HbA1c in the DEPAC
trial were slightly higher in the Polish population
and even worse in the population of central and
eastern European (CE) countries. We were unable
to perform a direct statistical comparison of these
trials. Additionally, we don’t have any data about
methodology of HbA1c assessment and its variabi-
lity constitutes the shortcoming of this registry.
The percentage of T1DM patients who fulfil-
led the criterion of HbA1c < 7.0% was higher in Re-
gistry than in the Polish and CE populations partici-
pating in the DEPAC trial [12]. Data shown in the
Swedish National Diabetes Registry showed even less
T1DM patients with HbA1c lower than 7.0% [13].
More strict criteria for HbA1c < 6.5%, what is re-
commended by the Polish Diabetological Associa-
tion for type 1 diabetes, met less than one-fourth of
T1DM patients what is still better than in the DE-
PAC study [12].
After publication of results of the ACCORD stu-
dy, as well as some other trials, the therapeutic go-
als for T2DM were reviewed. In the majority of pa-
tients, the recommended HbA1c target is below 7.0%
however the target below 6.5% can be considered
in T2DM patients with short duration of the dise-
ase. The percentage of T2DM patients achieving
HbA1c < 7.0% and < 6.5% in Registry was 52.1%
and 32.8%, respectively. This is much better than in
DEPAC’s Polish and CE populations [12].
The therapeutic goals in T1DM are focused
mostly on glycaemic control. Irregular daily activi-
ties related to the patient’s occupation or exercise
contribute to the problems with achieving targets
for glucose control. Despite of constantly improving
therapeutic resources targets have not been achie-
ved in many patients. At the current state of know-
ledge, the most important factor influencing outco-
mes in T1DM is patients’ compliance. This is best
seen in the most motivated group of patients: pre-
gnant women. In this population with T1DM coming
from our centre the mean HbA1c was 5.8% in 3rd
trimester [14].
The results of glycaemic control in the Western
Europe and USA seem to be at comparable levels.
Percentage of T2DM with HbA1c < 7.0% was sligh-
tly lower in Italy [15], Spain [16] and slightly better
in the USA [17, 18] and Germany [19]. HbA1c at more
strict level < 6.5 was achieved in less T2DM patients
in France [20] and Sweden [21] as compared with
the Polish Diabetes Registry for Adults.
Lipid abnormalities are very frequent in diabe-
tic patients. Haffner et al. found that type 2 diabe-
tics had risk of death similar to those who suffered
from myocardial infarction [22]. This is why recom-
mended values of the total and LDL-cholesterol are
more strict than in population without diabetes. The
PDA recommends LDL-cholesterol < 2.6 mmol/l for
most subjects with diabetes and < 1.8 mmol/l for
those with overt macroangiopathy.
In the Registry less than a half patients with
T1DM reached target values for LDL-cholesterol ho-
wever this value is better than in DEPAC. Patients
with T2DM in this Registry had a bit worse results
than T1DM but the results were much better than
Table 6. Chronic complications of diabetes
Chronic complication of diabetes Type 1 (n) (%) Type 2 (n) (%) type 1 & 2 (n) (%)
Microvascular
Retinopathy 1040 41.9 5376 26.6 6416 29.1
Nephropathy 971 17.7 5053 10.3 6024 11.5
Peripheral neuropathy 1134 25.3 6119 27.1 7253 26.9
Autonomic neuropathy 1134 9.6 6119 5.4 7253 6.0
Diabetic foot 1134 4.0 6119 2.7 7253 2.9
Macrovascular
Coronary heart disease 1005 10.7 5428 41.0 6433 36.3
Cerebral artery disease 988 3.5 5147 11.5 6135 10.3
Peripheral artery disease 983 5.3 4990 11.0 5973 10.0
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presented in DEPAC [12]. This improvement in Regi-
stry may be explained by better awareness of he-
alth care professionals and dropping costs of treat-
ment with statins what used to be a very important
limiting-factor of therapy in Poland. Despite of this
therapy number of patients with appropriate LDL-
-cholesterol level seems slightly disappointing. The
trials in other countries reveal similar or worse re-
sults. In Sweden 48% of type 1 diabetics had LDL-
-cholesterol within target. The percentage of patients
with type 2 diabetes who had satisfactory level of
LDL-cholesterol < 100 mg/dl varied from 5.9% in
Spain [16], 16.4% in Italy [15], 30.4% in Germany
[19] to 37.2% and 46.5% in the USA [17, 18].
Arterial hypertension is another significant risk
factor what contributes to the worse prognosis in
diabetic population [23, 24]. The upper range of the
target in the Registry was established at the level of
130/80 mmHg [25], that was recommended value
in 2009 year. Recently, there is evidence that inten-
se lowering of blood pressure in some subgroups
has at least no beneficial effect [26]. Results of blo-
od pressure control are poor as only 31.9% T1DM
and barely 12.9% T2DM patients achieved recom-
mended range. It is particularly disappointing in the
light of a wide variety of antihypertensive drugs on
market. Most of them are cheap and can be applied
to the majority of patients. Achieving appropriate
control of blood pressure seems more difficult than
control of glucose and lipids levels. In the previous
survey performed in Poland in 2003, only 5.2% of
T2DM subjects had satisfactory blood pressure me-
asures. The DEPAC trial showed that 42% of T1DM
and barely 9% of T2DM patients had appropriate
blood pressure control [12]. The results of similar
surveys performed in the Western European coun-
tries are diverse. The rate of satisfactorily controlled
blood pressure in type 2 diabetics was 7.8% in Spa-
in [16], 13% in Sweden [21], 14.4% in Italy [15],
27% in Germany [19] and 29% in France [20]. Much
better results were observed in the USA: 45,5% and
51.7% [17, 18].
According to the recent guidelines, metformin
is recommended in every treatment paradigm: as
monotherapy or in combination with other oral drugs
or insulin. Data presented above suggests that even
taking into account contraindications or side effects
of metformin, this drug is underused in T2DM popu-
lation. A very small number of patients were treated
with incretin axis drugs (GLP-1 receptor agonists or
DPP-IV inhibitors). This can be explained by the short
presence of these drugs on market and lack of reim-
bursement from the National Health Care system.
In T1DM patients rapid analogues were the
most frequent prandial insulins (69.3%) whereas
most frequent basal insulin was the NPH insulin
(53.6%). The percentage of patients treated with
long-acting analogues was significantly smaller,
what can be explained by lack of reimbursement by
the national health system in Poland. This makes
them unavailable for the majority of patients due
to high price. This explains why the use of these in-
sulins in all T2DM patients is at the level of 2.0%
and 3.6% of treated with insulin. Only 4.67% of
patients with T1DM were treated with personal in-
sulin pump. High costs of devices and disposable
sets that are not reimbursed for all T1DM popula-
tion limit the common use of insulin pump. None of
T2DM subject was treated with this method.
The most frequent microvascular complication
in Registry was retinopathy. In Poland the examina-
tion of eye background in diabetic patients is per-
formed by ophthalmologist. At least one annual
examination is recommended, more frequent visits
are advised in advanced stages of retinopathy. In
the Registry, any form of retinopathy was found in
more patients with T1DM than in T2DM and the
prevalence was comparable with results of DEPAC
[12]. In other surveys performed in western coun-
tries the prevalence of retinopathy was similar to
the current status [27–30].
Frequency of any nephropathy defined as pre-
sence of either albuminuria or/and elevated creati-
nine level was lower in Registry than in the DEPAC
project [12].
The frequency of neuropathy (diagnosed by the
presence of symptoms or signs or abnormalities in
nerve conduction studies) was slightly lower in T1DM
and similar in T2DM in Registry as compared to
DEPAC [12].
The prevalence of macrovascular complications
was very similar in the Registry and the DEPAC. Co-
ronary heart disease was found in 10.7% and 8.5%
in T1DM and 41.0% and 43.4% in T2DM, respecti-
vely. Cerebral artery disease was found in: 3.5% and
1.1% in T1DM and 11.5% and 7.2% in T2DM, re-
spectively. Peripheral artery disease was found in:
5.3% and 6.0% in T1DM and 11.0% and 15.6% in
T2DM, respectively [12].
The natural course of chronic complications of
diabetes runs in years and decades thus improve-
ment in epidemiological indices can be expected
after at least several years of significant improve-
ment in diabetes management.
In summary treatment outcomes of Polish dia-
betics in 2007–9 seems to show slight improvement
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with those presented in the DEPAC trial. It can be
explained by growing awareness about diabetes,
better access to medical care and improvement in
welfare of society, although, one should also point
out that the centres included into this registry were
not randomly assigned, what could have altered the
obtained results. Lack of reimbursement of some
modern treatment may constitute a barrier for fur-
ther improvement.
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